<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01296191</url>
  </required_header>
  <id_info>
    <org_study_id>2011-BV-A</org_study_id>
    <nct_id>NCT01296191</nct_id>
  </id_info>
  <brief_title>Aqueous Absorption and Pharmacokinetics of Besivance Versus VIGAMOX in Patients Undergoing Phacoemulsification</brief_title>
  <official_title>Aqueous Absorption and Pharmacokinetics of Besivance Versus VIGAMOX in Patients Undergoing Phacoemulsification</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Frank A. Bucci, Jr., M.D.</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Bucci Laser Vision Institute</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to compare drug concentrations in aqueous humor following ocular
      instillation of Besivance and VIGAMOX in subjects undergoing cataract surgery.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The objective of this study is to compare drug concentrations in aqueous humor following
      ocular instillation of Besivance or VIGAMOX in subjects undergoing cataract surgery. The
      hypothesis of the study is that the aggregate aqueous absorption of Besivance over a six hour
      period is greater than VIGAMOX because of unique properties of Besivance which promote
      increased contact time of this antibiotic with the ocular surface.

      Subjects with scheduled cataract surgery will be screened during their pre-operative visit.
      Eligible subjects will be randomized to treatment with Besivance or VIGAMOX. Subjects will
      self-administer 1 drop of study drug into the operative eye 4 times a day for 3 days prior to
      surgery.Subjects will have one final drop of study medication on the day of
      surgery.Immediately prior to beginning the cataract surgery, a sample of aqueous humor will
      be collected by paracentesis.Concentration of Besivance and VIGAMOX in the aqueous humor will
      be determined by an independent laboratory using standardized high pressure liquid
      chromatography and mass spectrometry assays. Pharmacokinetic parameters determined from the
      aqueous humor concentration-time data will minimally include the area under the curve and the
      maximum concentration.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>May 2011</start_date>
  <completion_date type="Actual">January 2013</completion_date>
  <primary_completion_date type="Actual">January 2013</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Single (Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Pharmacokinetics in Aqueous Humor Samples.</measure>
    <time_frame>Measured after 3 days of drug instillation</time_frame>
    <description>Concentration of Besivance and VIGAMOX in the aqueous humor will be determined by an independent laboratory using standardized high-pressure liquid chromatography and mass spectrometry assays. Pharmacokinetic parameters determined from the aqueous humor concentration will minimally include the area under the curve and the maximum concentration.</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">120</enrollment>
  <condition>Cataracts</condition>
  <arm_group>
    <arm_group_label>VIGAMOX</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Subjects undergoing cataract surgery, randomized to the VIGAMOX group Generic name is moxifloxacin eye drops, drops to be used 1 drop 4 times daily for 3 days prior to surgery and 1 drop on day of surgery.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Besivance</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Subjects scheduled for cataract surgery, randomized to the Besivance group Generic name is besifloxacin eye drops, drops to be used 1 drop 4 times daily for 3 days prior to surgery and 1 drop on day of surgery.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Moxifloxacin</intervention_name>
    <description>One drop 4 times daily for 3 days and one drop the day of sample collection</description>
    <arm_group_label>VIGAMOX</arm_group_label>
    <other_name>Vigamox</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>besifloxacin</intervention_name>
    <description>One drop 4 times daily for 3 days and one drop on day of sample collection</description>
    <arm_group_label>Besivance</arm_group_label>
    <other_name>Besivance</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Man or woman 18 years of age or older.

          -  Physically capable of instilling eye drop or have an appropriate person available to
             assist in administration of eye drops 4 times a day.

          -  Scheduled for phacoemulsification with intraocular lens (IOL) implantation for the
             treatment of cataract.

          -  Meet the American Society of Anesthesiology (ASA) physical status I, II, or III and be
             medically cleared for surgery.

          -  Willing to adhere to the prohibitions and restrictions specified in this protocol.

          -  Subjects must have signed an informed consent document indicating that they understand
             the purpose of and procedures required for the study and are willing to participate in
             the study.

        Exclusion Criteria:

          -  Known allergy or contraindication to the test article(s) or their components.

          -  Presence of any abnormality or significant illness in the eye that in the
             investigator's opinion could affect the subject's health or the study parameters.

          -  Presence of an active ocular infection (bacterial, viral or fungal), or positive
             history of ocular herpetic infection.

          -  History of any significant illness that could be expected to interfere with the study
             parameters. Any condition that, in the opinion of the investigator, would compromise
             the well-being of the subject or the study.

          -  Use of disallowed therapies (systemic or topical):

               -  Fluoroquinolone anti-infective agents (systemic or topical) within 1 week of
                  Visit 1 or anytime after Visit 1 for the duration of the study.

          -  Use of contact lenses for one week prior to the study and for the duration of the
             study.

          -  Received an experimental drug or used an experimental medical device within 10 days
             before the planned start of treatment.

          -  Breast-feeding
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>100 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Frank A. Bucci, Jr., MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Bucci Laser Vision Institute</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Bucci Laser Vision Institute</name>
      <address>
        <city>Wilkes-Barre</city>
        <state>Pennsylvania</state>
        <zip>18702</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>October 2019</verification_date>
  <study_first_submitted>February 14, 2011</study_first_submitted>
  <study_first_submitted_qc>February 14, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 15, 2011</study_first_posted>
  <results_first_submitted>January 24, 2013</results_first_submitted>
  <results_first_submitted_qc>October 10, 2019</results_first_submitted_qc>
  <results_first_posted type="Actual">October 29, 2019</results_first_posted>
  <last_update_submitted>October 10, 2019</last_update_submitted>
  <last_update_submitted_qc>October 10, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">October 29, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>Bucci Laser Vision Institute</investigator_affiliation>
    <investigator_full_name>Frank A. Bucci, Jr., M.D.</investigator_full_name>
    <investigator_title>Principal Investigator</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cataract</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Moxifloxacin</mesh_term>
    <mesh_term>Besifloxacin</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>VIGAMOX</title>
          <description>Subjects undergoing cataract surgery, randomized to the VIGAMOX group</description>
        </group>
        <group group_id="P2">
          <title>Besivance</title>
          <description>Subjects scheduled for cataract surgery, randomized to the Besivance group</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="60"/>
                <participants group_id="P2" count="60"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="57"/>
                <participants group_id="P2" count="59"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>VIGAMOX</title>
          <description>Subjects undergoing cataract surgery, randomized to the VIGAMOX group</description>
        </group>
        <group group_id="B2">
          <title>Besivance</title>
          <description>Subjects scheduled for cataract surgery, randomized to the Besivance group</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="60"/>
            <count group_id="B2" value="60"/>
            <count group_id="B3" value="120"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>&lt;=18 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Between 18 and 65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="9"/>
                    <measurement group_id="B2" value="12"/>
                    <measurement group_id="B3" value="21"/>
                  </measurement_list>
                </category>
                <category>
                  <title>&gt;=65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="51"/>
                    <measurement group_id="B2" value="48"/>
                    <measurement group_id="B3" value="99"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="35"/>
                    <measurement group_id="B2" value="28"/>
                    <measurement group_id="B3" value="63"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="25"/>
                    <measurement group_id="B2" value="32"/>
                    <measurement group_id="B3" value="57"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Pharmacokinetics in Aqueous Humor Samples.</title>
        <description>Concentration of Besivance and VIGAMOX in the aqueous humor will be determined by an independent laboratory using standardized high-pressure liquid chromatography and mass spectrometry assays. Pharmacokinetic parameters determined from the aqueous humor concentration will minimally include the area under the curve and the maximum concentration.</description>
        <time_frame>Measured after 3 days of drug instillation</time_frame>
        <group_list>
          <group group_id="O1">
            <title>VIGAMOX</title>
            <description>Subjects undergoing cataract surgery, randomized to the VIGAMOX group</description>
          </group>
          <group group_id="O2">
            <title>Besivance</title>
            <description>Subjects scheduled for cataract surgery, randomized to the Besivance group</description>
          </group>
        </group_list>
        <measure>
          <title>Pharmacokinetics in Aqueous Humor Samples.</title>
          <description>Concentration of Besivance and VIGAMOX in the aqueous humor will be determined by an independent laboratory using standardized high-pressure liquid chromatography and mass spectrometry assays. Pharmacokinetic parameters determined from the aqueous humor concentration will minimally include the area under the curve and the maximum concentration.</description>
          <units>ng/ml</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="57"/>
                <count group_id="O2" value="59"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="443.07" spread="232.285"/>
                    <measurement group_id="O2" value="56.4525" spread="39.6325"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Adverse events were collected from the start of the study medications until the aqueous collection. This time period is 4 days.</time_frame>
      <desc>Serious and Other (Not Including Serious) Adverse Events did not occur</desc>
      <group_list>
        <group group_id="E1">
          <title>VIGAMOX</title>
          <description>Subjects undergoing cataract surgery, randomized to the VIGAMOX group</description>
        </group>
        <group group_id="E2">
          <title>Besivance</title>
          <description>Subjects scheduled for cataract surgery, randomized to the Besivance group</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="60"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="60"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="60"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="60"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Frank A. Bucci Jr., MD</name_or_title>
      <organization>Bucci Laser Vision</organization>
      <phone>570-825-5949</phone>
      <email>buccivision@aol.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

